The pharmaceutical community is buzzing about Retatrutide 120 , a dual-action medication showing remarkable benefits in early studies . This new compound, a GLP-1 receptor agonist alongside a glucose-dependent insulinotropic agent , appears to notably lower body size and positively affect metabol